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Abstract
A series of polypyridyl complexes have been synthesized. All polypyridyl complexes
and some of the soluble ligands have been assayed for antitumor actiwty in vitro against
the HL-60 (the human leucocytoma), cells, BEL-7402 (the human liver carcinoma) cells,
KB (the human nasophangeal carcinoma) cells and HELA (the human adenocarcinoma
of cervix) cells. The results indicate that several complexes have relative activity aainst different cell lines. Especially, the complexes [Co(boy)z(pip)]+, [Co(phen)z(plp)]+,
[Ru(bpy)z(pztp)]+ and [Ru(pztp)(bpy)]
z+ show relative }/igh activity against four tumor
cell lines. Moreover, they are shghtly more effective than cisplatin. At the concentration of
100 lag/mL, the complexes show inhibitory rate of 7286% for the cancer cells and have
no toxicity for MDCK and Vero cells. It is indicated that these complexes can inhibit
cancer cells selectively.
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Introduction
Currently, cis-diaminedichlorplatinum(II) (cisplatin) is one of the three most widely
used anlttumor drugs in the world. It is highly effective in treating testicular and ovarian
cancers’. Despite its success, cisplatin has several disadvantages that include severe
toxicity such as nephrotoxicity, neurotoxicity, and emetogensis. The toxic side effects of
cisplatin limit the dose that can be given to patients. Another platinum-based antitumor_
drug, diamine[1,1-cyclobutanedicaboxylato(2-)]-platinum(II) (carboplatin), received
worldwide approval and achieved routine clinical use. Carboplatin is less toxic than
cisplatin and can be given at a much higher dose than cisplatin. Unfortunately, carboplatin
is still only }ctive n the same range of tumors as cisplatin and is still administered
intravenously. Thus, it is necessary to develop a new class of anticancer agents.
Some metal comple3s containing polypyridyl ligands are known to be bound with
DNA by intercalation. However, httle attentionhas.been paid to the anticancer activity
ofpolypyridyl metal complexes and a systematic investigation on the anticancer activity
and cytotoxcity of polypyridyl complexes is rare. In fact s,oe metal polypyridyl
complexes display remarkable antibacterial and antitumor activity’
In the present paper, we report for the fist time the cytotoxic activity of a series of
Ru(II) / Co(III) based polypyridyl complexes. It was expected to find a new type of
potential antitumor agent from these complexes.
Materials and methods
Complexes 12 2+13 3+ Synthesis of the ligand pytp and the 99molexes [Ru(L)2(ohtp)] [Co(L)2(ip)]
and [Co(L)2(pil]
+ (L bpy or phn+) have been described. Complexe, s
[Ru(bpy)2(pytp)] and [Ru(phen)2(pytp)] were synthesized similarly to a previously
described method’.
Synthesis of[Ru(bpy):(pytp)](Cl04) 16 OH 5 cm3 was 0.048 g (0.35 ltamol) of pyridine-2-carboxamide nyorazone in %21 [, )_
added to 10 cm of CH3CN solution of [Ru(bpy)z(phendione)](C104)2 (0.3 mmol, 0.260
g). The mixture was refluxed at 80C for 4 h and evaporated to dryness. The residue was
dissolved in CH3CN (5 cm3) and purified by column chromatography on alumina using
acetonitrile/toluene-(10:l) as-eluent. Yield: 0.167 g, 60%. Anal. Calcd tor
[Ru(bpy)z(pytp)](C104)2 C, 45.4; H, 3.16; N, 15.6. Found: C, 45.8; H, 3.32; N, 15.4.’H
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NMR (500 MHz, DMSO-d6): (ppm) 9.85 (d, 1 H), 9.76 (d, 18H)’.03
8.99 (m, 2 H), 8.61 (t, 4
H), 8.38 (d, 1 H), 8.33 (d, 1 H), 8.19 (t, 3 H), 8.09 (t, 2 H), (m, 2 H), 7.92 (d, 2 H),
7.77 (m, 3 H), 7.54 (t, 2 H), 7.34 (m, 2 H).
Synthesis of[Ru(phen)(pytp)](Cl04)
This complex was synthesized in a similar manner to mat oescrioealvtOr [Ru(bpy)z(pytp)](C104)2, with 0.3 mmol, 0.261 g of [Ru(phen)z(phendione)](C104)2 in
place of [Ru(bpy)z(phendione)](C104)2. Yield: 0.189 g, 65%. Anal. Calcd for [Ru(phen)z(pytp)](C104)2 C, 50.7; H, 2.59; N, 15.7. Found: C, 50.9; H, 3.09; N, 15.6. H
NMR(500 MHz, DMSO-d6): (ppm) 9.81 (d, 1 H), 9,73 (d, 1 H), 8.98 (m, 2 H), 8.70 (d, 2
H), 8.67 (d, 2 H), 8.33 (s, 4H), 8.30 (d, 2 H), 8.27 (d, 2 H), 8.19 (t, 1 H), 8.10 (d, 1 H),
8.08 (d, 1 H), 7.89 (m, 2 H), 7.72 (m, 5 H)
All other compJexes [Ru(bpy)z(dppz)]Z,
+
[Ru(phen)z(pztp)] and [Ru(pztp)z(bpy)] "-were synthesized according to literature
methods. Structures or some related hgands are illustrated in Chart 1. Elemental analyses
were performed on a Perkin-Elmer 240C elemental analyzer.
NH N
bpy phen ip
NN.NH
N N"L"O
pip dppz ohtp
N,,.N
N
N
pytp pztp
Chart 1. Structures of the polypyridyl ligands
Solvents were purified by standard techniques and were freshly distilled prior to use.
Other chemicals used are analytical reagents ofhighpurity grade.
For experiments the complexes were dissolvedin freshly prepared in 10 % DMSO,
and diluted to the required concentration with culture when used. The stock solutions in
distilled water were stored at +4C. The solutions in growth medium used in the
experiments were prepared extempore. Cisp,atin was used as a reference compound and its
solutions were prepared as described above-.
Cells and tumor cells
The four tumor cells strains HL-60 (the human leucocytoma) cell line, BEL-7402 (the
human liver carcinoma) cell line, KB (the human nasopharyngeal carcinoma) cell line, and
344Metal Based Drugs Vol. 7, Nr. 6, 2000
HELA (the human adenocarcinoma of cervix) cell line were provided by the National Key
Laboratory ofNatural and Bionic Drugs, Beijing Medical University.
Madin-Darby Canine Kidney MDCK cells and Vero cells were obtained from the
Chinese Academy of Military Medical Sciences.
The cells and tumor cells were cultured at 37C as monolayers in RPMI-1640 medium
(Flow Laboratories, USA) supplemented with antibiotics (penicillin and streptomycin) and
10% bovine serum. Serum concen’ation was reduced to 5% for growth of cells and tumor
cells and for testing the complexes ".
Cytotoxicity assay ofthe compounds
The compounds were dissolved in RPMI-1640 containing 2% Calf serum, filtered
to remove germs, and diluted with cell maintenance medium to obtain the solution with
different concentrations. Having formed a single layer, MDCK and Vero cells were
digested b’ pancreatin and counted, then made into a 2x10 cells/ml suspension and
inoculated n the wells of flat-bottomed 96-well plastic culture tray (0.1 ml/well), thereafter
incubated at 37C in a thermotank containing 5% CO2 for 24 h. After the cells had formed
single layers, the original culture medium was removed and replaced with maintenance
medium containing various concentrations of the compounds. After further incubatj)n for
5-7 days, the number of the living cells was calculated by MTT staining method The
maximum nontoxic concentration (TC0) and the 50% toxic concentration (TC0) were also
calculated.
Antitumor activity assay ofthe compounds
The complexes and cisplatin were assayed for cytotoxicity in vitro against The four
tumor cells strains HL-60 (the human leucocytoma) cell line, BEL-7402 (the human liver
carcinoma) cell line, KB (the human nasopharyngeal carcinoma) cell line, and HELA (the
human adenocarcinoma of cervix) cell line. The procedure for antitumor activity studies
was similar to that reported earlier2’24. Briefly, in order to calculate the concentration of
each rug that produces a 50% inhibition of cell growth (IC0), 100 1 of cell suspension
(4x10 cell/ml) were exposed to various concentrations of complexes dissolved in sterile
water. After incubation periods of 72 h for all cell lines, the cell concentrations were
determined both in control and in drug-treated cultures. All experiments were made in
quadruplicate.
The results show that several complexes have relative activity against different cell
lines.
Table 1. Cytotoxicity values of the polypyridyl complexes
MDCK
Complexes
YC0(tmol/L) YC0(mol/L)
Vero
TC0(lamol/L) TCs0(Bmol/L)
[Co(bpy)2(ip)]+ 480 690 450 650
[Co(bpy)2(pip)]
3+ 420 630 430 620
[Co(phen)2(pip)]
3+ 380 540 360 540
[Co(phen)2(ip)]+ 490 560 470 520
[Ru(bpy)z(dppz)]
2+ 390 480 400 500
[Ru(phen)z(dppz)]
2+ 450 650 420 6 0
[Ru(bpy)z(ohtp)]_+ 320 460 340 490
[Ru(bpy)z(pztp)]
2+ 360 480 380 500
[Ru(phen)z(pztp)]
2+ 350 480 380 500
[Ru(pztp)z(bpy)]2_
+ 380 500 390 520
[Ru(bpy)z(pytp)]+ 320 400 360 460
[Ru(phen)z(pytp)]
2+ 300 410 350 480
All the complexes are in perchlorate form except that [Co(bpy)2(pip)] and [Co(phen)2(pip)] are in
chloride form.
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Results
All complexes are characterized by elemental analyses, UV-Vis spectroscopy and
NMR spectroscopy and are in accordance with their proposed formula.
Cytotoxicity and antitumor activity ofthe complexes
Microscopically according to the survival rates, the maximum nontoxic concentration (TCo) and the
50% toxic concentration (TC0) of the complexes can be calculated by Reed-Muench method, and the results
are listed in Table 1.
Microscopically the MNC for complexes was determined as 300 490 tmol / L for
MDCK cells and 340 470 lamol / L for Vero cells (Table 1). Additional data were found
when the viability of cells was studied. The number of viable MDCK cells and Vero
cultured in complexes medium was increased during the whole period of investigation as
compared to that of untreated control. Moreover, the viability was significantly increased
when the concentration ofACV was decreased. This is well manifested after 48 and 72 h.
In contrast, all complexes tested were toxic low for MDCK and Vero cell.
Polypyridyl complexes have been tested against four tumor cell lines. They were
exposed to cells for 72 h and growth inhibition was assessed usinu the sulforhodamine B
protein staining assay2. The corresponding 50% inhibitor dose (Iff0) values are shown in
Table 2. Cisplatin is also included for comparison.
The complexes [Ru(phen)z(dppz)]2, [Ru(bpy)(ohtp)]2+, [Ru(phen)z(pztp)]
z+ and
[Ru(phen)z(pytp)]
z+ showed high IC0 values against all tested four_ cell lines, indicating
that they have no,biological activity. Yhcomplexes [Co(bpy)z(pip)]3+, [Co(phen)z(pip)],
[Ru(pztp)z(bpy)] and-[Ru(bpy)z(pztp)] have much more lower IC0 values against HE-
60 cell line. M_oreover, they are slightly more effective than cisplatin. The_ complexes
[Co(,bpy_)z_(pip)]+, [Co(phen)z(pip)] 3+, [Ru(pztp)z(bpy)]+ and [Ru(bpy)z(pztp)]
z+ displayed
similar IC0 values (7.3, 9.4, 9.8 and 6.7 _gmol/L respectively) against HL-60 cell fine to
cistlatin (6.0 gmol/L), indicatin that the four olypyridyl complexes could be considered
to have same cyt.toxic activity. ’in addition, although the complexes [Co(bpy)z(pip)]+ and
[Ru(bpy)z(pztp)] showed higher IC0 values (8.9 and 6.9 gmol/L respectively) against
KB cellline than cisplatin (1.3 ttmol/L), they still exhibited good cytotox[c activity.
2+ 2+ It is very interesting that [ku(bpy)z(dppz)] and its sister complex [Ru(bpy)z(dppz)]
do not show any significant inhibition against all of the tested cll,Jines despite that they
are proven DNA intercalators and bind to DNA avidly (K > 10). Furthermore, bein
associated with DNA electrostatically r3, [Ru(bpy)z(ohtp)]
z’+ is non-active against the ceil
lines either. DNA bin,i.1}gltudies suggested that the other complexes should be bound with
DNA by intercalation ’ ’ , bu_tz+their antitumor activities’ against the cell lines are diverse.
For instance,. [Ru(bpy)z(pp]zt ) s.hows much more hig.her activity gaainst all of the four
cell lines than [Ru(phen)z(pztp)]
2 an spte of the smlarty of their structures. The results
indicate clearly that the antitumor mechanisms of these complexes should be different and
the central metal ions, the ligands and the shape of the complexes should play a role in the
mechanism. Moreover, since all of these polypyridyl complexes bind to DNA non-
covalently, the antitumor mechanisms should also be different from that of cisplatin.
Recently published data also show that the inhibition of antitumor activity by polypyridyl
ruthenium or cobalt was enhanced by reducing agents and that the mechanism of the
activation is similar to that for polypyridyl complexes mediated DNA damage.
Conclusion
Twelve polypyridyl metal complexes have been synthesized and characterized. These
complexes have been tested in vitro against HL-60 (the human leucocytoma) cell line,
BEL-7402 (the human liver carcinoma) cell line, KB (the human nasopharyngeal
carcinoma) cell line and HELA (the human adenocarcinoma of cervix) cell line. It has been
found that if an appropriate pol,pyridyl ligand is bound to Ru(II) or Co(III), the
corresponding complex could exhllit a significant antitumor.effect. The present study
indicates for the first time that polypyridyl metal complexes have significant cytotoxic
activity. We believe our results may contribute to the development of a new class of
antitumor agents.
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Table 2. 72 h IC0 values obtained for the polypyridyl complexes and cisplatin against
different tumor cells lines
Complexes
ICso(ktmol/L)
b
HL-60 BEL-7402 KB HELA
[Co(bpy)2(ip)]
3+
[Co(bpy)2(pip)]
3+
[Co(phen)2(pip)]
3+
[Co(phen)2(ip)]
3+
[Ru(bpy)2(dppz)]2+
[Ru(phen)z(dppz)]
2+
[Ru(bpy)2(ohtp)]
2+
[u(bpy)2(pztp)]2+ ! u(phen)2(pztp)12+
[Ru(pztp)2(bpy) _
+
[Ru(bpy)2(pytp)]+
[Ru(phen)2(pytp)]2+
57.8* >100" 18.9"* 10.4"*
7.3** 13.2’* 8.9** 12.6"*
9.4** 34.6 54.6* 32.5*
92.6* >100" >100"
92* >100" >100"
6.7** 12.6"* 6.9** 12.3"*
>100" >100"
9.8** 6.5** 12.3"* 24.5**
65.4* 9.6** 14.6"* 6.8**
98.6* >100’ >100" >100"
6.5 7.7 1.3 6.9 Cisplatin
a. All the complexes are in perchlorate form except that [Co(bpy)2(pip)]
3+ and [Co(phen)_(pip)]
3+ are in
chloride form. b. The 50% inhibitory concentration (ICs0) is defined as concentration that suppresses
tumor cells by 50%. c. The inhibitory rate against tumor cells less than 50% at testing concentration of
the complexes.
p 0.5 p<0.05
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